Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.
about
Calcium intake and bone mineral density: systematic review and meta-analysisLoss of life years after a hip fracture.Plate on plate osteosynthesis for the treatment of nonhealed periplate fractures.Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a reviewManagement of osteoporosis in patients hospitalized for hip fracturesPrevention and treatment of postmenopausal osteoporosis.Vitamin D in health and disease: current perspectives.Sex and gender considerations in male patients with osteoporosisReview of ibandronate in the treatment of osteoporosis.The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men.Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agentsBaseline age and time to major fracture in younger postmenopausal women.Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities.Osteoporotic fracture and parathyroid hormone.Teriparatide (1-34 human PTH) regulation of osterix during fracture repair.Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based AnalysisBMD screening in older women: initial measurement and testing intervalCost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence.The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapyPrevention of osteoporosis-related fractures among postmenopausal women and older men.Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trialsConsensus statements on osteoporosis diagnosis, prevention, and management in the Philippines.Antiresorptive therapies for osteoporosis: a clinical overview.Effects of increasing age, dosage, and duration of PTH treatment on BMD increase--a meta-analysis.Emerging drugs for osteoporosis.Agreement between fragility fracture risk assessment algorithms as applied to adults with chronic spinal cord injury.Osteoporosis guidelines.Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis.Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug.Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifen.The effectiveness of intermittent rat parathyroid hormone (1-34) treatment on low bone mass due to oestrogen or androgen depletion in skeletally mature rats
P2860
Q26784337-60243DFC-54FB-49BF-B877-3A96C40A3B59Q33660935-2372D622-987D-4708-AECC-7995AC285174Q33710623-6013534F-44FA-424D-AF0F-D298F5C5CB39Q34271979-DE32F593-C91E-48CE-A753-CA22722EE6A8Q34284002-6C93CFF2-2EF4-4E00-A07E-1F994E5399DFQ34296614-BD803EF8-16AC-4F5E-B147-FB86CFB0BEDAQ34481617-B28285B2-8044-4D33-9CD1-99FD857B6591Q35036493-CFDAF6CD-9D85-43C1-BE60-8E8851F3DA3FQ35076601-3CB05824-86C6-4D04-9E47-69D7A78495E3Q35110262-FA78FE59-1B0E-41D7-8507-B8C854E14D86Q35229871-24975B74-7249-479B-BC24-F20498A1F382Q35542877-7EA06A02-862C-47E1-9592-65BFE23E68FAQ35663909-3F076FFE-7C5C-4990-AAAA-CC6DF6872B30Q35775369-BC388860-161D-4798-86AB-08CF069830C5Q35825410-837B85CA-0754-44B5-9F4F-EE8E5F296EECQ35915566-63AD9D44-9553-4491-97DF-5AE3958DD96BQ36045845-CB8C29CE-A527-4BBC-8FE6-D39F3ABA68C2Q36630230-75983D31-24FE-43D2-9BB9-20D66BF34F96Q36763643-D6FF92D4-D350-483B-A328-DA8419B5A369Q36829073-95323C9C-F432-43F2-9E74-390A85B0A3DDQ37428448-3ED28599-44AD-480B-AEDE-5ED366CB4E56Q37454589-168E61E4-E0FA-4DBC-93E6-1C4F62815835Q37911560-56BA0355-7B0A-4FB8-A5F8-67FE54106298Q37926914-7AA3B3D3-7A73-409A-A13D-BE7B07EBBDCBQ37975163-3C29F07A-4233-49A4-9036-AD644F95EAA4Q38226342-F970A44A-9831-43A8-8F4D-D94BDF94DD2CQ40162458-A431C6A0-319C-4576-B9AF-EC485CFFAFE1Q42875457-B163463A-00DA-4037-B0A0-1D604AAD3916Q43950222-B0CDBF2E-2DA3-45B9-B843-A9180A0A1406Q44818567-0808C207-631B-4DB7-9F54-1DF78903699DQ48322047-CE18EFF6-0FF1-44EC-B441-4C4BD135EB3FQ53669167-D0026749-693C-452A-A59F-F4CC821104FEQ58294828-AC9C4522-A86F-46D7-9D5D-5BE4C85072E7
P2860
Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@ast
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@en
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@nl
type
label
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@ast
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@en
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@nl
prefLabel
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@ast
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@en
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@nl
P2093
P356
P1433
P1476
Meta-analyses of therapies for ...... f postmenopausal osteoporosis.
@en
P2093
Ann Cranney
Beverley Shea
Bruce Weaver
George Wells
Jonathan Adachi
Nicole Zytaruk
Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group
Vivian Robinson
P304
P356
10.1210/ER.2001-4002
P577
2002-08-01T00:00:00Z